Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1664-1671

  Smith, David C ^a   Esper, Peg ^a   Strawderman, Myla ^a   Redman, Bruce ^a   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HORMONE RESISTANCE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033001992     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1664     Document Type: Article

References (31)

1. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
2. Eisenberger MA, Kennedy P, Abrams J: How effective is cytotoxic chemotherapy for disseminated prostatic carcinoma? Oncology 1:59-71, 1987
3. Hartley-Asp B, Kruse E: Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 9:387-395, 1986
4. Vogelstein B, Pardoll DM, Coffey DS: Supercoiled loops and eucaryotic DNA replication. Cell 22:79-85, 1980
5. Pienta KJ, Coffey DS: A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci 1:123-135, 1984 (Suppl)
6. Robinson SI, Small D, Idzerda R, et al: The association of transcriptionally active genes with the nuclear matrix of the chicken oviduct. Nucleic Acids Res 11:5113-5130, 1983
7. Ciejek EM, Tsai MJ, BW OM: Actively transcribed genes are associated with the nuclear matrix. Nature 306:607-609, 1983
8. Nelson WG, Liu LF, Coffey DS: Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 322:187-189, 1986
9. Earnshaw WC, Heck MM: Localization of topoisomerase II in mitotic chromsomes. J Cell Biol 100:1716-1725, 1985
10. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625, 1993
11. Rutberg M, Friden B, Bjork P, et al: Proteolytic cleavage of high-molecular-weight microtubule-associated proteins by the prostatic estramustine-binding protein. Prostate 15:287-297, 1989
12. Slevin ML: The clinical pharmacology of etoposide. Cancer 67:319-329, 1991
13. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate [see comments]. J Clin Oncol 12:2005-2012, 1994
14. Pienta KJ, Redman BG, Bandekar R, et al: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50:401-406, 1997
15. Dimopoulos MA, Panopoulos C, Bamia C, et al: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50:754-758, 1997
16. Tew KD, Stearns ME: Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 15:155-160, 1987
17. Fakih M, Yagoda A, Replogle T, et al: Inhibition of prostate cancer growth by estramustine and colchicine. Prostate 26:310-315, 1995
18. Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
19. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
20. Amato R, Logothetis C, Sella A, et al: Preliminary results of a phase II trial of estramustine (EMCYT), vinblastine (VLB) and mitomycin-C (MMC) for patients (pts) with progressive androgen-independent prostate carcinoma (AIPCa). Proc Am Assoc Cancer Res 34:A1213, 1993 (abstr)
21. Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992
22. Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone-refractory carcinoma of the prostate: A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457-2460, 1993
23. Hudes GR, Nathan F, Khater C, et al: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156-3163, 1997
24. Pienta KJ, Naik H, Lehr JE: Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology 48:164-170, 1996
25. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
26. Esper P, Mo F, Chodak G, et al: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50:920-928, 1997
27. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457, 1958
28. Ellerhorst JS, Tu S-M, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997
29. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
30. Dowling AJ, Panzarella T, Tannock IF: Relationship between changes in serum prostatic specific antigen (PSA) and palliative response following treatment of symptomatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 17:A1248, 1998 (abstr)
31. Petrylak DP, Shelton G, Judge T, et al: Phase I trial of docetaxel (D) + estramustine (E) in androgen-insensitive prostate cancer (AIP). Proc Am Soc Clin Oncol 16:A1103, 1997 (abstr)